Fhit expression protects against HER2-driven breast tumor development: Unraveling the molecular interconnections

Cell Cycle

Volumn 6, Issue 6, 2007, Pages 643-646

  Bianchi, Francesca ^a   Tagliabue, Elda ^a   Ménard, Sylvie ^a   Campiglio, Manuela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast tumors; EGFR; Fhit; HER2; Signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; GENOMIC DNA;

BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER INHIBITION; CANCER MODEL; GENE AMPLIFICATION; GENE FREQUENCY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METHYLATION; NONHUMAN; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

MOUSE MAMMARY TUMOR VIRUS; MUS; RATTUS;

EID: 34047236049     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.6.4033     Document Type: Review

References (55)

1. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: From gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3:748-54.
2. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, Mccue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site acid renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84:587-97.
3. Siprashvili Z, Sozzi G, Barnes LD, Mccue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94:13771-76.
4. Campiglio M, Bianchi F, Andriani F, Sozzi G, Tagliabue E, Ménard S, Roz L. Diadenosines as FHIT-ness instructors. J Cell Physiol 2006; 208:274-81.
5. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM, Huebner K. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 2001; 98:10250-55.
6. Vecchione A, Sevignani C, Giarnieri E, Zanesi N, Ishii H, Cesari R, Fong LY, Gomella LG, Croce CM, Baffa R. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 2004; 10:7607-12.
7. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Hueber K, Croce CM. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001; 61:4827-36.
8. Ishii H, Mimori K, Inoue H, Inageta T, Ishikawa K, Semba S, Druck T, Trapasso F, Tani K, Vecchione A, Croce CM, Mori M, Huebner K. Fhit modulates the DNA damage checkpoint response. Cancer Res 2006; 66(23):11287-292.
9. Zanesi N, Mancini R, Sevignani C, Vecchione A, Kaou M, Valtieri M, Calin GA, Pekarsky Y, Gnarra JR, Croce CM, Huebner K. Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. Cancer Res 2005; 65:6576-82.
10. Druck T, Hadaczeck P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese MI, Rosen D, Rothstein J, Mccue P, Cotticelli MG, Inoue H, Croce CM, Huebner K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997; 57:504-12.
11. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996; 85:17-26.
12. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, Croce CM, Pierotti MA. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57:5207-12.
13. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. The Oncologist 1998; 3:237-52.
14. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathological significance of FHIT protein expression in stage I nonsmall cell lung carcinoma. Cancer Res 1998; 58(23):5478-5483.
15. Tseng JE, Khuri F, Kemp B, Liu D, Hong WK, Mao LMD. Loss of pFhit expression is frequent but not associated with prognosis in stage-I nonsmall cell lung cancer (NSCLC). AACR Proceedings 1999; 184, (Ref Type: Abstract).
16. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of Fhit expression in nonsmall-cell lung cancer: Correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000; 82:1191-97.
17. Pylkkanen L, Wolff H, Stjernvall T, Tuominen P, Sioris T, Karjalainen A, Anttila S, Husgafvel-Pursiainen K. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int J Oncol 2002; 20:285-90.
18. Chen YJ, Chen PH, Lee MD, Chang JG. Aberrant FHIT transcripts in cancerous and corresponding noncancerous lesions of the digestive tract. Int J Cancer 1997; 72:955-58.
19. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, Santoro E, Croce CM, Huebner K. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998; 58:4708-14.
20. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K, McCue PA. Fhit expression in gastric adenocarcinoma: Correlation with disease stage and survival. Cancer 2000; 88:24-34.
21. Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG, Cho MH. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 2001; 284:850-55.
22. Lee SH, Kim CJ, Park HK, Koh JW, Cho MH, Baek MJ, Lee MS. Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med 2001; 33:124-30.
23. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Munoz N, Bosch FX, Shah K, Cho KR. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997; 57:4692-98.
24. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999; 59:5270-74.
25. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Munoz N, Cho KR. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000; 6:3505-10.
26. Yoshino K, Enomoto T, Nakamura T, Sun H, Ozaki K, Nakashima R, Wada H, Saitoh J, Watanabe Y, Noda K, Murata Y. FHIT alterations in cancerous and noncancerous cervical epithelium. Int J Cancer 2000; 85:6-13.
27. Krivak TC, McBroom JW, Seidman J, Venzon D, Crothers B, MacKoul PJ, Rose GS, Carlson JW, Birrer MJ. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: A poor prognostic factor. Cancer Res 2001; 61:4382-85.
28. Baykal C, Ayhan A, Al A, Yuce K, Ayhan A. No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma. Int J Gynecol Cancer 2003; 13:192-96.
29. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, Yang SC, Wong YK, Lin SC. Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol 2002; 196(3):300-6.
30. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56:3173-79.
31. Hayashi S, Tanimoto K, Hajiro-Nakanishi K, Tsuchiya E, Kurosumi M, Higashi Y, Imai K, Suga K, Nakachi K. Abnormal FHIT transcripts in human breast carcinomas: A clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 1997; 57:1981-85.
32. Campiglio M, Pekarsky Y, Ménard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with an advantages stage of the disease. Cancer Res 1999; 59:3866-69.
33. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kononen J, Kallioniemi OP, Barkardottir RB, Kovatich AJ, Schwarting R, Hauck WW, Huebner K, McCue PA. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 1999; 59:2682-89.
34. Gatalica Z, Lele SM, Rampy BA, Norris BA. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 2000; 88:1378-83.
35. Yang Q, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Nakamura M, Nakamura Y, Wang X, Mori I, Sakurai T, Kakudo K. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 2001; 7:3869-73.
36. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, Shimizu Y, Mori I, Sakurai T, Kakudo K. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 2002; 8:2890-93.
37. Luan X, Shi G, Zohouri M, Paradee W, Smith DI, Decker HJ, Cannizzaro LA. The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma. Oncogene 1997; 15:79-86.
38. Eyzaguirre EJ, Miettinen M, Norris BA, Gatalica Z. Different immunohistochemical patterns of Fhit protein expression in renal neoplasms. Mod Pathol 1999; 12:979-83.
39. Ramp U, Caliskan E, Ebert T, Karagiannidis C, Willers R, Gabbert HE, Gerharz CD. FHIT expression in clear cell renal carcinomas: Versatility of protein levels and correlation with survival. J Pathol 2002; 196:430-36.
40. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61:3581-85.
41. Roa JC, Anabalon L, Roa I, Melo A, Araya JC, Tapia O, de AX, Munoz S, Schneider B. Promoter methylation profile in gallbladder cancer. J Gastroenterol 2006; 41(3):269-75.
42. Wali A, Srinivasan R, Shabnam MS, Majumdar S, Joshi K, Behera D. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Mol Cancer Res 2006; 4(2):93-99.
43. Bianchi F, Magnifico A, Olgiati C, Zanesi N, Pekarsky Y, Tagliabue E, Croce CM, Menard S, Campiglio M. FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci USA 2006; 103:18981-6.
44. Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, Huebner K, Barnes LD, Croce CM. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 2004; 101:3775-79.
45. Sauer T, Beraki K, Noren T, Garred O, Naess O. EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. Diagn Cytopathol 2005; 33(4):228-32.
46. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 2003; 10:1-21.
47. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000; 182:150-62.
48. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005; 18(8):1027-33.
49. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22:6570-78.
50. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74.
51. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchinal network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16:5276-87.
52. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006; 439(7073):168-74.
53. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15:2452-67.
54. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R. Evaluation of the united states food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7(6):1669-75.
55. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89:10578-82.